Hinova Pharmaceuticals Future Growth
Future criteria checks 2/6
Hinova Pharmaceuticals is forecast to grow earnings and revenue by 10.2% and 126.4% per annum respectively. EPS is expected to grow by 10.4% per annum. Return on equity is forecast to be -22.8% in 3 years.
Key information
10.2%
Earnings growth rate
10.4%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 126.4% |
| Future return on equity | -22.8% |
| Analyst coverage | Low |
| Last updated | 19 Sep 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 363 | -167 | N/A | -252 | 1 |
| 12/31/2025 | 163 | -227 | N/A | -308 | 1 |
| 12/31/2024 | N/A | -234 | N/A | -300 | 1 |
| 9/30/2024 | 0 | -210 | -327 | -195 | N/A |
| 6/30/2024 | 0 | -229 | -347 | -226 | N/A |
| 3/31/2024 | N/A | -266 | -357 | -252 | N/A |
| 12/31/2023 | N/A | -294 | -355 | -256 | N/A |
| 9/30/2023 | 2 | -317 | -435 | -324 | N/A |
| 6/30/2023 | 2 | -319 | -399 | -295 | N/A |
| 3/31/2023 | 2 | -290 | -381 | -306 | N/A |
| 12/31/2022 | 2 | -302 | -384 | -315 | N/A |
| 9/30/2022 | N/A | -319 | -345 | -294 | N/A |
| 6/30/2022 | N/A | -306 | -334 | -295 | N/A |
| 3/31/2022 | N/A | -343 | -300 | -265 | N/A |
| 12/31/2021 | N/A | -306 | -248 | -228 | N/A |
| 12/31/2020 | N/A | -490 | -246 | -244 | N/A |
| 12/31/2019 | 4 | -112 | -83 | -81 | N/A |
| 12/31/2018 | 4 | -39 | -19 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688302 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688302 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688302 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688302's revenue (126.4% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688302's revenue (126.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688302 is forecast to be unprofitable in 3 years.